Ipsen Showcases Neurological Advancements at TOXINS 2026

At the TOXINS 2026 conference in Madrid, Ipsen presented 14 abstracts detailing advancements in neurological care. The presentation covered various conditions like post-stroke spasticity, cervical dystonia, and blepharospasm. Dysport® (abobotulinumtoxinA) was a focal point, highlighting its role in improving patient outcomes.

An interim analysis from the EPITOME trial revealed that 45.7% of stroke survivors with paresis developed post-stroke spasticity within a year. This data underscores the importance of early monitoring and intervention, as less than 1% of these patients currently receive BoNT-A treatment as standard practice.

Remote monitoring tools such as the Post-stroke Spasticity Monitoring Questionnaire aim to enhance early detection and management, potentially improving rehabilitation and patient quality of life. Ipsen continues to commit to bridging care gaps in neurological diseases.